Stereotaxis (STXS) Q3 2026 Earnings Call Transcript

Stereotaxis (STXS) reported Q3 2026 revenue growth of 60% YoY, driven by sales of GenesisX and Synchrony systems. Key milestones include FDA clearance for GenesisX interoperability and a collaboration with Canon. Robotic catheter revenue is expected to reach several million dollars this year, despite supply constraints. The company anticipates resolving supply issues in early 2027 and sees growth opportunities in capital systems and disposable revenue.

Original reporting
Published Nov 11, 2026, 4:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 4:18 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Stereotaxis (STXS) Q3 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$STXSBullishMed
01

Why it matters

The earnings beat and partnership could drive short-term price upside, but supply chain issues remain a risk.

02

Market read

Earnings and partnership news provide a fresh catalyst for STXS, with modest upside potential.

03

What to watch

Potential delays in scaling Osypka's production could dampen future growth.

Relevance 6/10Novelty 7/10Timing: after-hours today

Background

Stereotaxis reported its Q3 2026 earnings, highlighting revenue growth, FDA clearance, and a new collaboration with Canon.

Company-level read

Ticker impact

$STXSBullishHigh confidence
Context

Q3 2026 earnings call disclosed system revenue of $3M, up 60% YoY, and new FDA clearance and Canon collaboration.

Expected impact

potential modest upside as investors price in higher-than-expected revenue and new partnership news

Evidence & confidence

Fresh earnings numbers and concrete partnership announcements provide a clear catalyst.

Market effects

Positive signal for medical robotics and interventional cardiology equipment sector.

U.S. and European markets may see modest gains in healthcare equipment stocks.

Limited to niche medical device segment.

Counterpoint

Revenue growth may be offset by supply constraints and limited catheter availability.

Key entities

  • Canon

    Collaborating on X‑ray compatibility for GenesisX system.

  • Osypka

    Facing production shortfalls for MAGIC catheters.

Related articles

$STXSHigh

Why is Stereotaxis stock sliding today?

Stereotaxis (STXS) fell 14.6% after Q3 2026 results missed estimates, with a $0.07 adjusted loss per share and $8.9M revenue. Supply shortages of MAGiC catheters and a $24M convertible note financing at $1.21/share raised concerns. TD Cowen cut its price target to $2.00. The stock hit a 52-week low of $0.80.

$STXSMedAI 8/10

20 robotic heart procedures had no device-related adverse events.

Stereotaxis (NYSE: STXS) announced 100% clinical success and no device-related adverse events in 20 first-in-human robotic heart procedures using Robocath's next-generation system. The study, presented at TCT 2026, showed 95% technical success and no physician radiation exposure. Robocath is a subsidiary of Stereotaxis, focusing on advanced robotic innovations for interventional cardiology.

$STXSMedAI 8/10

Stereotaxis (STXS) Q2 2026 Earnings Call Transcript

Stereotaxis (STXS) reported Q2 2026 revenue of $7.7M, down from $8.8M YoY due to no robotic system delivery. Robotic catheter revenue grew 270% sequentially to $1M. Recurring revenue increased to $6.2M. Gross margin was 58%. The company expects cash flow profitability by H1 2027 and guided Q3/Q4 recurring revenue at $7M and $8M, respectively. Management highlighted supply constraints and transition risks.

$STXSMed

Stereotaxis Reports 2026 Second Quarter Financial Results & Business Updates

Stereotaxis, Inc. (STXS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Stereotaxis Reports 2026 Second Quarter Financial Results & Business Updates ● Robotic catheter revenue surpasses $1M in the quarter, growing 270% sequentially ● First GenesisX robotic system purchase by US hospital to be installed this fall ● Multiple Synchrony digi

$NIUMed

Niu Tech (NIU) Q3 2026 Earnings Call Transcript

Niu Tech (NIU) reported Q3 2026 earnings, with total sales volume up 15.4% YoY to 534,057 units. Revenue was RMB 1.71 billion, up 1.2% YoY. China sales grew 8.6% YoY, while international sales surged 226%. Gross margin expanded to 18.0%. The company highlighted strong growth in electric motorcycles, which accounted for 56% of China sales, and strategic product launches.